Phases, active trials: Phase 1: 71, Phase 2: 50, Phase 3: 92, Other: 16
Eli Lilly has transformed its portfolio with two breakthrough platforms: GLP-1/GIP receptor agonists for obesity and diabetes (tirzepatide/Mounjaro, retatrutide, orforglipron) and targeted oncology (Verzenio/abemaciclib in breast cancer, Retevmo/selpercatinib for RET-altered cancers, Jaypirca/pirtobrutinib for B-cell malignancies). The obesity franchise is generating an unprecedented volume of Phase 3 trials across cardiometabolic, liver disease, sleep apnea, kidney disease, and other conditions. In immunology, Omvoh (mirikizumab) for IBD and Olumiant (baricitinib) expansions add breadth beyond oncology and metabolic disease.
- Obesity / metabolic disease (GLP-1/GIP)
- Oncology (breast, RET-altered, BTK)
- Immunology / IBD
- Diabetes
- Alzheimer's disease (donanemab)
- Mounjaro / Zepbound (tirzepatide) — GLP-1/GIP dual agonist
- Verzenio (abemaciclib) — CDK4/6 inhibitor, breast cancer
- Retevmo (selpercatinib) — RET inhibitor, NSCLC/thyroid/other
- Jaypirca (pirtobrutinib) — non-covalent BTK inhibitor
- Omvoh (mirikizumab) — IL-23p19, IBD
- Donanemab — anti-amyloid beta, Alzheimer's
Monitor the Eli Lilly pipeline daily
Get a daily digest when Eli Lilly registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Obesity | 43 |
| Overweight | 36 |
| Healthy | 19 |
| Alzheimer Disease | 13 |
| Neoplasm Metastasis | 11 |
| Breast Neoplasms | 9 |
| Diabetes Mellitus, Type 2 | 9 |
| Breast Cancer | 7 |
Lilly's tirzepatide/GLP-1 platform is the fastest-growing new drug class in history by trial volume. Any company developing obesity, metabolic, or cardiorenal therapeutics needs close visibility into Lilly's expanding label trials. Their oncology pipeline (Verzenio combinations, Retevmo expansions) also generates consistent new Phase 2/3 registrations.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Eli Lilly's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Eli Lilly may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Eli Lilly pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 | Recruiting | Interventions modified | 2026-09-05 |
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With… NCT05614739 | Recruiting | Trial arms changed: 5 → 8 | 2026-08-21 |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes… NCT06897475 | Recruiting | Completion pushed: 2027-01 → 2027-06 | 2026-09-15 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight… NCT07153471 | Recruiting | Trial sites reduced: 96 → 88 locations | 2026-09-09 |
| A Study of LY3439539 in Participants With Alzheimer's Disease NCT07598370 | Recruiting | Trial sites expanded: 8 → 11 locations | 2026-09-05 |
Each trial page shows every change DataLookout has recorded for that trial.